is trying to figure out what I want to be IF I grow up.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At this point, I'm not counting on KCPC providing anything to support me in my retirement, but I'll keep on hoping to be pleasantly surprised. Company appears to have viable product and good intentions, but whether they have the influence and connections to parlay those into a successful business remains to be seen.
Check out the latest press releases on the newly modified key Capital website. Latest one was November 10th: https://keycapitalcorp.com/new-direction-for-key-capital/
Actually, years before Key Capital became involved in Crypto, they were focused on precious metals streaming...a royalty based model like Franco Nevada. Unfortunately that part of the business didn't prove very successful....at least not that I'm aware of. I've stayed around because of the cancer treatment and other work with Immunitor. Have not invested any money in any of their Crypto projects. I'm intrigued by Gold Crypto...but haven't seen enough evidence that they've got their to act together to participate. I've asked several times over the years if KCPC actually has any ongoing gold or silver streaming contracts...but never get an answer. I was thinking that would be the source of all the physical gold they've said would back Gold Crypto...but radio silence.
Not a single mention on the board of Wednesday's press release. I guess I'll post it: https://finance.yahoo.com/news/key-capital-launches-maxcelllife-com-133000875.html
Jennifer Reilly appointed Marketing Director to Lead MaxCellLife.com LaunchNEW YORK, NY / ACCESSWIRE / April 7, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) ...
I thought this was going to be a post on Trump's dancing.
New email from KCPC Mail List!
If you haven't clicked on the link at the top of the message board to get on the mail list. An email arrived from Peter Boonen this morning. Very hopeful sounding. It said "Click Here to View in Browser". So I'm hoping the resulting link works: https://mailchi.mp/5ac33f3f3018/welcome-to-key-capital-2021?e=f5b08a0bdc
As wonderful as it was to see my Roth 401k jump a whole lot today, I treated it as a mirage because with the low volume and the SEC suspension I knew it was just a fleeting thing.
You should probably dump whatever shares you've got left for whatever you can get before they become worthless. I'd be happy to take them off your hands, and spare you the misery of watching your investment go down the toilet.
You should probably dump whatever shares you've got left for whatever you can get before they become worthless. I'd be happy to take them off your hands, and spare you the misery of watching your investment go down the toilet.
Sounds like a fair evaluation. I don't understand the mechanics of how the grey market works. Maybe the only thing that's changed about the stock is that it now has a big Scarlet letter tattooed on its forehead until such time as they officially clear the current status and restore its good name.
I'm not 100% sure where it trades. Last time I bought some in July, I just placed an order in my Ameritrade account, and somebody somewhere executed the buy.
https://keycapitalcorp.com/key-biotec-website-launch/
KEY CAPITAL LICENSES IMMUNITOR ORAL PILL IMMUNOTHERAPEUTICS
Key Capital to advance development of breakthrough patented oral pill immunotherapeutics
New York, NY November 23, 2020 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that Key Biotec, a division of Key Capital, has entered into agreement with Immunitor group interests (“Immunitor”) to exclusively license its breakthrough patented oral tableted immunotherapeutics platform products for North, Central and South America (excluding Canada), the EU (excluding UK), Australia and New Zealand (the “Territory”).
Immunitor is recognized as a pioneer in oral tableted immunotherapeutic science, having over the past 20 years developed 23 disease treatments that are in various stages of clinical development. In each case, the patented platform immunotherapeutics have consistently demonstrated success in diseases such as late stage and terminal cancers, tuberculosis, HIV/AIDS, hepatitis, and influenza, regularly offering better outcomes than current pharmaceutical options. This has been most significant, in many cases where current treatment options have failed or performed poorly.
Market: The major potential for the immunotherapeutics is in the prescription drug market, forecast to exceed US$1,500 billion by 2026, and in the vaccination market which is forecast to grow to US$104 billion by 2027.
Oral tableted immunotherapeutics: Immunitor immunotherapeutics primarily target the body’s mucosal and innate immunity for broad and effective protection against invading pathogens and diseased cancer cells. This is achieved through the Immunitor proprietary technology platform enabling the active in oral tablets form to be protected from digestive degradation in the gastrointestinal tract, thereby providing optimal access to the gut mucosa/microbiome which is responsible for the body’s primary immune response functions.
Compelling use case: Immunitor immunotherapeutics treat disease and/or viral or bacterial infection through activation and optimization of the body immune system through its gut mucosa/microbiome. The oral pill platform technology overcomes the gut mucosa delivery challenges, promises superior immunotherapeutic performance, offers improved safety in having no side effects or toxicity, and avoids undesirable immune effects such as cytokine storm and autoimmune conditions. The patented oral tableting technology also provides major development and consumer cost benefits.
The many peer-reviewed publications of Immunitor clinical studies support the safety, performance, and enhanced efficacy of the Immunitor products comparative to current alternatives, which provide for the underlying use and commercialization potential to be quite dramatic.
Development history of Immunitor immunotherapeutics: The Immunitor journey for oral tableted immunotherapeutics development, pioneered by Dr. Aldar Bourinbaiar and Vichai Jirathitikal, commenced 20 years ago with an oral immunotherapeutic for HIV/AIDS. Since then Immunitor has progressively refined its technology and successfully trialed and patent-protected its products.
The clinical studies, funded through angel investors, were conducted largely in Mongolia and the Ukraine, leveraging major research cost advantages. The research has additionally been supported by three grants jointly from the Canadian government and the Bill and Melinda Gates Foundation, and also grants from the US State Department’s Science & Technology Entrepreneurship Program award, the Ukraine Ministry of Science, and several through private foundations/interests.
A core attribute of Immunitor’s patented platform technology is that almost any immunotherapeutic product can be manufactured and ready for clinical trials within weeks, as the Immunitor platform technology allows for a safe inactivated whole or part pathogen, virus, or other agent to be readily incorporated within the patent protected tableting process of the Immunitor platform technology.
Current regulatory situation: Several hundred thousand people to date have used Immunitor oral tableted immunotherapeutics in limited countries where some Immunitor products are approved for sale, further confirming safety and efficacy. The Western and larger markets will require further and more extensive formal studies to secure the FDA (USA), EMA (EU), or TGA (Australia) registrations needed to allow marketing in these regions.
USA FDA: In the USA, Immunitor does not have any regulatory approvals for any of its products, however three Immunitor oral pill immunotherapeutics, Tubimod and Mycobacterium vaccae, each for treatment of TB, and Hepko-V5 for treatment of Hepatocellular carcinoma have current US FDA Orphan Drug Designation; and 16 clinical study trials for various indications, including many for cancers, are listed on https://clinicaltrials.gov/ct2/results?term=immunitor.
Advantages of Immunitor immunotherapeutics include: The development timelines, costs for individual products, and time to market can be dramatically reduced, with further benefits including: Improved safety as products are not chemical compounds; Potential for better outcomes; Cost is a fraction of most other treatments and therefore affordable to larger populations; Oral pills are room temperature stable and do not require cold-chain custody, transportation or storage; Pill manufacturing can easily scale up to multi-millions of doses per day; Needle-free and not requiring clinical administration; Overcomes needle phobia; Self-administration can dramatically enhance scalability.
Key Biotec licensing and partnering: Key Capital Corporation Chairman, Peter Boonen stated: “Immunitor’s patented platform technology and their 20-year successful development of the science and product candidates to date, provides a solid business case and an extraordinary opportunity for the Company and Key Biotec. We look forward to supporting Immunitor in progression of its three FDA Orphan Drug Designated candidates, and in further development of its oral tablet immunotherapeutics portfolio products throughout our licensed Territory, and for our mutual benefit in accordance with our License Agreement partnering.”
Jonathan Wong, Lead Scientific Advisor and Immunitor consultant who formerly headed development of novel antimicrobial drugs against intracellular pathogens including pandemic viruses for the Canadian government at DRDC Suffield added: “The potential for progressing a class of oral pill immunotherapeutic disease treatment products that are safe and effective is exciting, however of more importance is getting these products approved and to market.”
COVID-19, viruses, and infectious disease: Infectious diseases represent a major threat to human lives as seen by the rapid pandemic spread of COVID-19 to more than 58 million infections and some 1.4 million deaths. There is no doubt the world will regularly be subject to further future pandemic threats. In this regard a key attribute of the Immunitor Immunotherapeutic platform is that being oral pill therapeutic vaccines that are not pharmaceutical compounds, they can be readily formulated, trialed, and subject to approvals, easily and cost effectively mass distributed.
A novel and groundbreaking Immunitor oral tableted immunotherapeutic vaccine is currently being studied for SARS-CoV-2/COVID-19 in several Asian regions. Significant potential advantages of this oral pill immunotherapeutic vaccine, subject to continued development success, are its safety, its highly advantageous time-to-market and cost benefits, its mass-market distribution scalability, and that it is therapeutic as well as most likely prophylactic.
Key Capital Corporation: The Company Chairman is currently leading a Company reorganization focused on securing dynamic proven corporate and pharma industry management. The Company’s immediate operational objective will be the further development of the oral pill immunotherapeutics opportunity within its Territory in association with its Immunitor partnering, and particularly on advancing the Orphan Drug Designated cancer candidate, along with early focus on disease conditions with unmet needs.
Regarding the current trading situation of the Company’s securities, the Company will be working with its advisors to ensure reinstatement of trading is resumed within the next six months.
For further information see: https://keybiotec.com and https://keycapitalcorp.com
For all inquiries please contact:
Key Capital at: +1 (646) 401-0177, or Peter Boonen, Chairman at: peter@keycapitalcorp.com
Disclaimer: Statements made in this press release that express the Company or management’s intentions, plans, beliefs, expectations, or predictions of future events, are forward-looking statements. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will” and similar expressions are intended to further identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Those statements are based on many assumptions and are subject to many known and unknown risks, uncertainties and other factors that could cause the Company’s actual activities, results or performance to differ materially from those anticipated or projected in such forward-looking statements. The Company cannot guarantee future financial results, levels of activity, performance or achievements and investors should not place undue reliance on the Company’s forward-looking statements.
So can you put both a limit sell AND a stop loss in place on the same shares simultaneously?
Here's a suggestion I just followed from the Yahoo Finance board with the shares in my and my wife's Roth IRA accounts: "Just a suggestion for all the Longs - Put a Sell Stop in at a relatively high price (say around $120); this will keep all the Shorts from borrowing your stocks."
Please forgive me if someone else posted that already. I put the sell limit order in at $120 as suggested.
I am a well known bagholder. I never take profits when I should, and ride stocks down while more savvy traders swoop in and make lots of money in a short time on stocks I've held for years. THIS time I decided to sell half the shares in our Roth IRA's at around $22.50. YAY! Made some money for a change. Bought back in at $14.65 earlier today. I do believe the lunatic in the oval office will manage to precipitate some sort of crisis that sends the market into yet another tailspin like in mid-March. I wish I knew when to go to cash........
I would appreciate if whoever put that big red flashing KCPC SEC SUSPENSION graphic at the top of the page would remove it. The suspension is ended, and therefore the warning is no longer in force. The SEC has seen fit not to extend the suspension, and leaving it up there is a disservice to those of us who are still maintaining belief in the company.
Anyone who might still be interested in the stock has access to all posts and all opinions on this board, and can do their own due diligence and make their own decisions about investing....IF they can find a way to trade the stock while it's listed on the grey market.
Leaving that up there now that the suspension has been lifted holds the rest of this board hostage to your opinion, and it isn't fair. So PLEASE remove that.
You think maybe they meant spin-off?
Why is this board unable to show the correct price or list trades? Still showing GRWG price at $4.85
Hey justbecause. I was under the impression that you are an East Coast guy. Has the hurricane cut into your fishing life at all?
Surprised the MM's havent taken this back down low again with a 100 share trade.....but the market is still open for one more minute......
Is this board still functioning? Total silence for a week now. Guess maybe everyone got weary of idle speculation in the absence of meaningful news. Hopefully something will come along to breathe some life into the trading.... and take it out of the hands of the market makers and their whims.
Methinks the market makers are playing with this. A few days ago, I had an order in at $.12. Part of it filled, and the remaining 1900 share offer just sat there. I played around....changed my bid to $.10 which never moved.....then raised it to $.115 for a day. Again, no nibbles. I went ahead and got the rest of my order filled at the ask of $.15, which filled immediately. A few minutes later....after no trades for several days....1,000 shares sold around $.06.
Strange that I couldn't pick up shares at a higher price (my order was NOT all or none)........and yet someone immediately pulled the share price down again with a low ball sell. Guess until we get some real news and some consistent volume, this sort of nonsense can be expected.
Will be curious to see how renewed talks with China impact rare earth stocks this coming week. I'm unclear if the risk of having Chinese supplies curtailed will still loom large....
I honestly don't know. Was on the road all day yesterday, and wasn't paying much attention as I had an unanticipated car repair to deal with. I think several of the financial newsletters have been promoting rare earth stocks because of all this mess with the Chinese and their control of so much of the existing capacity.
Been holding this stock for at least a year now with a minor loss. This China business has given me some hope on the rare earth front, and now there are some suggesting that uranium could also create a positive upside.
https://www.google.com/url?sa=i&source=web&cd=&ved=2ahUKEwifuan06vriAhWEVN8KHUY4AGsQzPwBegQIARAC&url=https%3A%2F%2Fwww.caseyresearch.com%2Farticles%2Fturmoil-in-the-uranium-sector-offers-huge-upside%2F&psig=AOvVaw0lY0fcmZoQWdKSZymX-vRn&ust=1561215451128220
I don't think the website is quite ready for prime time yet. If you click on the little menu in the upper right-hand corner, it brings up a navigation menu that doesn't seem to link to anything yet.
Latest from Darcy at Telegram about 9 p.m. last night: "Email is ready to go. Just waiting on GoldVault website to go live. Then will be sending out today."
After wading through the looooooong string of messages on the Telegram feed for GoldSecure, there seems to be a reasonable expectation that a relevant website update was supposed to materialize today...and an accompanying PR to go out......and now maybe today OR tomorrow due to developers being slammed.
goldsecure.io still gives the "coming soon" message when you click on the BUY GOLD button. No GoldVault website yet that I can see....but hopefully all will be revealed soon. One of Darcy's comments on Telegram: "As per the announcement it'll be 10th June."
Guess with all the investors champing at the bit, it might be better for them to wait until they actually have something to release rather than making apologies for missed dates.
Noteworthy that the Goldsecure group on Telegram has almost 500 members. No idea how significant that is. Could just be some people join anything with the word gold in the name, but maybe it also indicates a whole lot of interest building.
I enjoy the discussion jb. Always a learning experience for me. Guess I take it as a hopeful note that you're still hangin' around.
I will admit to having wondered why money wasn't being thrown at this when early results were so promising. I also realize that when one sells out to the big money interests, control is lost. There are still altruistic people out there who don't want to hand their labor of love off to bottom line types who might corrupt it, and write secret memos about how their actuaries have determined that it's cheaper to pay off X number of wrongful death lawsuits than fix the product.
Did you know that glyphosates (e.g. Roundup) were patented as an antibiotic? https://gmoanswers.com/ask/why-did-monsanto-patent-glyphosate-antibiotic-also-medical-establishment-has-been-preaching Now it's not only an herbicide, but is also sprayed on crops to make them dry more quickly and make it more efficient and economical to harvest them....thus increasing the amount that gets into our food chain.
And now glyphosates are heavily linked to cancer and the increasing disaster of antibiotic resistance. That's what happens when big money takes over. And now a "lucky" few lottery winners are reaping millions and billions in jury awards as their bodies are eaten up by cancer.
BUT OFF MY SOAPBOX....lol. You are clearly a far more sophisticated investor than I'll ever be. WHAT KEEPS YOU AROUND? What do you see as credible potential for KCPC?
I know you own a lot of shares justbecause, so I'm not sure why you feel compelled to ridicule this. I say that in the nicest way, because I truly value your input on this board, and continue to learn from you.
"To get FDA approval for a new treatment method, someone (pharmaceutical companies) must pony up the $10 Million plus and log 4–6 years walking the item through clinical trials." There is a lot of regulatory baggage and special interests to overcome when trying to navigate approval at nice shiny hospitals and research centers in the USA. The pharmaceutical companies have a lot invested in protecting their expensive treatments that kill at least as many people as they save. In the U.S system, this vaccine might never see the light of day....unless maybe a pharmaceutical company bought it.
I too had Googled the hospital, and accepted that it wasn't a prime candidate for a sexy photo in a glossy annual report.......although it may well be proudly displayed in one if this treatment lives up to the impressive statistics in the PR. People will be lined up at a mud hut if this vaccine delivers those kind of results at the rates claimed.
I think I would have liked to see a better headline in the PR. A lot of people don't read very far if the headline doesn't grab their attention, and I think it sounds like maybe the vaccine is much earlier in the trial process than is actually the case. So it goes. Always easy to be an armchair quarterback. Here's hoping this vaccine saves a lot of lives and brings a lot of hope.
Thanks! I'll give it a try. Wife has been giving a drop of her tincture to our dog as well, and it seems to be helping both her and the dog's arthritis.
Is anybody aware of any sort of reviews on their CBD products? I'd love to support the company. My wife has been taking CBD oil and CBD tinctures for well over a year now, and the products at Singleseed.com have some very nice pricing compared to what I've been paying, but I have no idea if the products are actually effective or good quality. I sold most of my shares of Singlepoint quite a few months ago after holding them for a couple of years. The dilution just got too ridiculous, but I'd still like to support them and I do have a few thousand shares left.
I don't allow my passwords to be saved in Chrome either. And where I write them down in my Outlook or Gmail address book with hints to remind me what the passwords were, I replace characters with asterisks and use the wrong number of asterisks so they can't guess based on number of characters.... just in case my address book is ever hacked.
And like you, I have 2FA anytime I log in to Coinbase or Bittrex for crypto stuff
Thanks AOA! As a former boss used to tell me, "That is above average thinking."
Ruezim....Perhaps another point of discussion as you seem to have good lines of communication. By way of intro to my thought process here, I remember avoiding use of password tracking apps for obvious reasons, and lo and behold some of them were hacked recently: https://www.komando.com/happening-now/547660/hackers-find-security-flaws-in-5-popular-password-managers-are-you-safe
In reading about round-up app products like Digit, Acorns and Revolute....they have access to checking or debit/credit cards to grab that bit of spare change to round things up. I have a little paranoia on that front because two years ago a stranger opened up a Venmo account using my checking account info and stole $2,000 from my checking account in the blink of an eye. I had never signed up for Venmo, and it was a rude surprise.
So any of those round-up apps have potential hackable access to my financial accounts in my paranoid imagination. I know Chris has an extensive background in cyber-security, and it might be nice to know how that may come into play and give GoldVault an edge over similar apps AND protect me if I begin to use the app once it's available.
You can google BNET and Chris Nichols for some insight into his cybersecurity background dating back at least 20 years....probably longer. Here is one instance: https://www.thefreelibrary.com/TIE+Technologies+Comment+On+Internet+Core+Servers+Attack.-a093531234
I’ve been doing some reading to wrap my head around these round up apps discussed in KCPC's latest news relase. The GoldVault deal does look promising, especially with Key Capital’s aligned involvement in mining. KCPC started out as a precious metals streaming company, and they have a lot of expertise in sourcing gold supplies at advantageous prices. After reading the articles that I’ve linked at the end here, I’m pretty excited about the opportunity to sign on. I currently use a feature with my Wells Fargo account that transfers $1.00 to my savings account every time I write a check or use my debit card. It’s a nice way of accumulating some extra savings……but the investment potential of some of these new round-up financial apps adds the potential of investing/leveraging those savings more effectively. And one of the articles talks about a feature where you can use the app to fund pre-tax retirement accounts. Anyway….here’s some info I’ve found. I think it will give you a better idea about how many people out there are flocking to these new alternatives to the old banks.
Offering gold accounts is not new – but doing this as ‘gold savings accounts’ that pays 9% per annum in gold is novel and potentially a game changer in what is a massive traditional global savings market that in many places pays less than 2% in annual interest.
Logic suggests that having an account in gold with (1) its upside value potential AND (2) getting 9% interest could position GoldVault to quickly capture a good share in the savings market
The ‘Round Up’ App angle tackles the savings market sector that is sweeping the world as this market targets the many millions that currently do not save. A 2017 Go Banking Rates article highlights the opportunity in USA and other western countries would be expected to have similar statistics – 57% have less than $1,000 in their bank Account and 39% have zero – this is a potential massive market (Seehttps://www.gobankingrates.com/about/press-releases/americans-less-1000-savings/).
Round Up accounts are simply accounts tied to your debit card that “rounds off” each purchase to the next whole dollar and deposits the difference into your savings account – in the case of GoldVault this is in gold as I understand it. The rounding up at least makes saving easier and almost not noticeable for the millions that are currently not saving – seems to make sense.
The Round Up market is reported to be largely pioneered by Acorns, and started gaining solid traction from 2017 with many of the mainstream banks joining in as well – such as JPMorgan (Finn); BoA (Keep the Change); Lloyds (Save the Change), and ING (Everyday Round Up).
Seemingly typical of this Round Up sector, Acorns has raised over $200 million; has about 5m Accounts; billion USD valuation, but is not yet operationally profitable. Similarly, Revolute raised US$71m in Oct 2017 at a valuation of US$350m, then a further US$250m at a valuation of US$1.7B just six months later and has since doubled its accounts to over 4 million in the past 12 months - but is also yet to report sustainable profits. It will be interesting to see how the GoldVault deal compares operationally as this information becomes available.
Figure that with an interest rate of 3 to 4 times that of bank savings accounts, it should not be long after they launch that GoldVault will have a quick 3 or 4 million accounts – and then what value would it be? Looks like a great Key Capital opportunity for the share deal announced.
Some Quick Search links – there are many and DYOR:
https://mashable.com/2017/03/25/savings-apps-review/#n8d0RChR8sq1
https://www.cnbc.com/2019/01/28/fintech-start-up-acorns-valued-at-860-million-after-latest-funding-round.html
https://finance.yahoo.com/news/spare-change-investing-app-acorns-now-manages-1-billion-195554934.html
https://www.forbes.com/sites/oliversmith/2018/04/26/how-nikolay-storonsky-took-revolut-from-350m-to-a-1-7bn-valuation-in-just-six-months/#d1c05c86aa32
I agree it would be nice if there was a little bit more idiot's guide type explanation regarding how you would go about investing in GoldVault. How do you deposit and withdraw money? How liquid are your funds if you want to withdraw them?
It all sounds conceptually wonderful at one level, but I don't fully understand how the mechanics would work, and I think that may be one thing that will make it difficult for people to say this is a great idea to invest in.
I think Chris and Associates are just too close to this, and don't quite understand the need to dumb it down for the man on the street. Reminds me of a PhD electrical engineer who was called upon to teach a class of marketing trainees I was in about basic electricity at a lighting company I used to work for. At the moment the basics here are just a little bit over my head, and I'll bet it's the same for a lot of other people.
Thanks for the positive thoughts WinstonCup. I got into this purely as an investment....but if it so happened that this vaccine helps cure a family member, an added benefit! My mother died of liver cancer. Outlived their 1-year life expectancy prediction by going on a macrobiotic diet, and lived 7 more years. She finally got sick of the diet, and said she wanted her steak and her chocolate, and died 6 months later. Men in my family almost all die from colon cancer....so one can always hope this will turn out to be the beginning of the end of a lot of cancer deaths.
This 2018 disclosure statement covers the broad strokes about KCPC's financial interest: http://www.otcmarkets.com/financialReportViewer?symbol=KCPC&id=193526
From page 4: "The Company in March 2017 announced a licensing agreement with Immunitor Inc. for rights to immunotherapy
vaccines to treat a variety of conditions, initially for the territory of Guatemala and Cost Rica."
I guess that means that KCPC will earn royalties for all of the vaccine sold in those two countries....in exchange for having provided funding to help develop the vaccine.